Supernus Pharmaceuticals (SUPN) Price & Analysis

Compare

509 Followers

SUPN Stock Chart & Stats

Day’s Range― - ―

52-Week Range$29.16 - $45.60

Previous CloseN/A

Volume41.90K

Average Volume (3M)969.44K

Market Cap

$2.49B

Enterprise Value$1.29B

Total Cash (Recent Filing)$522.60M

Total Debt (Recent Filing)$31.77M

Price to Earnings (P/E)38.8

Beta0.66

Next Earnings

Mar 03, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.91

Shares Outstanding56,073,090

10 Day Avg. Volume854,079

30 Day Avg. Volume969,441

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.52

Enterprise Value/Revenue1.95

Enterprise Value/Gross Profit2.36

Enterprise Value/Ebitda7.80

Forecast

1Y Price Target

$42.80

Price Target Upside-3.43% Downside

Rating ConsensusModerate Buy

Number of Analyst Covering5

Bulls Say, Bears Say

Bulls Say

Market PotentialGiven the need for non-stimulant ADHD options, Qelbree could eventually capture a significant portion of the total ADHD prescribing market.

Revenue GuidanceSUPN raised revenue guidance to $670-700 million, reflecting strong Qelbree performance and acquisition of Zurzuvae.

Sales PerformanceQelbree achieved $77.6MM in Q2 sales, exceeding consensus and showing strong growth.

Bears Say

Clinical Study ResultsFor SPN-820 in depression, the Phase IIb study showed a modest result that was not statistically significant, questioning its impact.

Seasonal DynamicsQelbree trends reflect normal seasonal dynamics, with a temporary decline that should improve, encouraging growth in the following quarters.

Supernus Pharmaceuticals News

Supernus reports Q2 EPS 40c vs. 36c last year

Reports Q2 revenue $165.5M, consensus $154.08M. “Our strong operating performance in the first half of the year was...

23d ago

SUPN

Supernus raises FY25 revenue view $670M-$700M from $600M-$630M

Consensus $636.35M. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>...

23d ago

SUPN

Supernus completes acquisition of Sage Therapeutics

Supernus (SUPN) Pharmaceuticals has completed its previously announced acquisition of Sage Therapeutics (SAGE). “Sage is an ideal fit...

28d ago

SAGE

SUPN

Cantor upgrades Supernus on outlook for ADHD treatment

Cantor Fitzgerald analyst Kristen Kluska upgraded Supernus (SUPN) to Overweight from Neutral with a price target of $42,...

30d ago

SUPN

Supernus upgraded to Overweight from Neutral at Cantor Fitzgerald

Cantor Fitzgerald upgraded Supernus (SUPN) to Overweight from Neutral with a price target of $42, up from $36....

30d ago

SUPN

Supernus Pharmaceuticals’ Earnings Call Highlights Growth Amid Challenges

Supernus Pharmaceuticals (($SUPN)) has held its Q2 earnings call. Read on for the main highlights of the call....

22d ago

SUPN

Supernus Pharmaceuticals Reports Strong Q2 2025 Results

Supernus Pharmaceuticals ( ($SUPN) ) has released its Q2 earnings. Here is a breakdown of the information Supernus...

23d ago

SUPN

Supernus Pharmaceuticals (SUPN) Q2 Earnings Cheat Sheet

Supernus Pharmaceuticals (SUPN) is scheduled to report 2nd quarter earnings on 08/05/2025, after the market closes. Regarding Q2...

25d ago

SUPN

Supernus Pharmaceuticals Completes Acquisition of Sage Therapeutics

Supernus Pharmaceuticals ( ($SUPN) ) has shared an update. On July 31, 2025, Supernus Pharmaceuticals completed its acquisition...

28d ago

SUPN

Supernus announces expiration of HSR waiting period for Sage Therapeutics

Supernus Pharmaceuticals (SUPN) announced that the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as...

1M ago

SAGE

SUPN

Sage Therapeutics cutting over 330 jobs, Boston Globe reports

Sage Therapeutics (SAGE) is laying off most of its employees after announcing its planned acquisition earlier this month,...

2M ago

SAGE

SUPN

Supernus Pharmaceuticals Holds Annual Stockholders Meeting

Supernus Pharmaceuticals ( ($SUPN) ) has issued an update. On June 16, 2025, Supernus Pharmaceuticals held its annual...

2M ago

SUPN

H.C. Wainwright sees potential competition for Sage from Biogen

H.C. Wainwright analyst Douglas Tsao says that while a takeover of Sage Therapeutics (SAGE) comes as no surprise,...

2M ago

BIIB

SAGE

Sage Therapeutics price target raised to $9 from $8 at Truist

Truist analyst Joon Lee raised the firm’s price target on Sage Therapeutics (SAGE) to $9 from $8 and...

2M ago

SAGE

SUPN

SUPN FAQ

What was Supernus Pharmaceuticals’s price range in the past 12 months?

Supernus Pharmaceuticals lowest stock price was $29.16 and its highest was $45.60 in the past 12 months.

What is Supernus Pharmaceuticals’s market cap?

Supernus Pharmaceuticals’s market cap is $2.49B.

When is Supernus Pharmaceuticals’s upcoming earnings report date?

Supernus Pharmaceuticals’s upcoming earnings report date is Mar 03, 2026 which is in 187 days.

How were Supernus Pharmaceuticals’s earnings last quarter?

Supernus Pharmaceuticals released its earnings results on Aug 05, 2025. The company reported $0.908 earnings per share for the quarter, beating the consensus estimate of $0.47 by $0.438.

Is Supernus Pharmaceuticals overvalued?

According to Wall Street analysts Supernus Pharmaceuticals’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Supernus Pharmaceuticals pay dividends?

Supernus Pharmaceuticals does not currently pay dividends.

What is Supernus Pharmaceuticals’s EPS estimate?

Supernus Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Supernus Pharmaceuticals have?

Supernus Pharmaceuticals has 56,073,090 shares outstanding.

What happened to Supernus Pharmaceuticals’s price movement after its last earnings report?

Supernus Pharmaceuticals reported an EPS of $0.908 in its last earnings report, beating expectations of $0.47. Following the earnings report the stock price went up 13.083%.

Which hedge fund is a major shareholder of Supernus Pharmaceuticals?

Currently, no hedge funds are holding shares in SUPN

Supernus Pharmaceuticals Stock Smart Score

Neutral

Fundamentals

Return on Equity

6.38%

Trailing 12-Months

Asset Growth

5.06%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age. The company's commercial products also comprise Qelbree, a selective norepinephrine reuptake inhibitor indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in pediatric patients 6 to 17 years of age; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, its product candidates include Qelbree (SPN-812), which has completed Phase III clinical trials that is used for the treatment of ADHD; SPN-830, a late-stage drug/device combination product candidate for the prevention of off episodes in PD patients; SPN-817, a novel product candidate in Phase I clinical trials for the treatment of severe epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; and SPN-443 and SPN-446, which are in preclinical stage for treating CNS. The company markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. The company was incorporated in 2005 and is headquartered in Rockville, Maryland.

Supernus Pharmaceuticals (SUPN) Earnings & Revenues

Historic Earnings Reports

SUPN Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

Supernus Pharmaceuticals reported a strong Q2 2025 with significant achievements such as the launch of ONAPGO, acquisition of Sage Therapeutics, and robust growth in key products like Qelbree and GOCOVRI. However, challenges remain with declines in legacy product sales, increased operating expenses, and a projected operating loss for 2025. Overall, the positive developments and future growth potential outweigh the negatives.View all SUPN earnings summaries

SUPN Stock 12 Month Forecast

Average Price Target

$42.80

▼(-3.43% Downside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"28":"$28","49":"$49","33.25":"$33.3","38.5":"$38.5","43.75":"$43.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":48,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$48.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":42.8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$42.80</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":36,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$36.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[28,33.25,38.5,43.75,49],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,35.5,36.46153846153846,37.42307692307692,38.38461538461539,39.34615384615385,40.30769230769231,41.26923076923077,42.23076923076923,43.19230769230769,44.15384615384615,45.11538461538461,46.07692307692308,47.03846153846154,{"y":48,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,35.5,36.06153846153846,36.62307692307692,37.184615384615384,37.746153846153845,38.30769230769231,38.86923076923077,39.43076923076923,39.99230769230769,40.55384615384615,41.11538461538461,41.676923076923075,42.238461538461536,{"y":42.8,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,35.5,35.53846153846154,35.57692307692308,35.61538461538461,35.65384615384615,35.69230769230769,35.73076923076923,35.76923076923077,35.80769230769231,35.84615384615385,35.88461538461539,35.92307692307692,35.96153846153846,{"y":36,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":29.57,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.16,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.97,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.31,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.16,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.37,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.06,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.68,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.45,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.91,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.82,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.5,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >